Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
Status:
Active, not recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well ferumoxytol magnetic resonance imaging (MRI) works
in assessing response to pembrolizumab in patients with glioblastoma. Diagnostic procedures,
such as ferumoxytol MRI, may help measure a patient's response to pembrolizumab treatment.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University